HRTX HERON THERAPEUTICS, INC. /DE/
Pharmaceutical Preparations · Nasdaq · SEC CIK 818033 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.4%
TTM net income YoY-58.8%
TTM EPS YoY-22.2%
Revenue 3-yr CAGR6.5%
Net income 3-yr CAGR—
Margins
Gross margin71.5%
Operating margin-5.7%
Net margin-14.5%
FCF margin-9.7%
EBITDA margin-4.4%
Returns
ROE-217.8%
ROA-9.0%
ROIC (approx.)—
Asset turnover0.62x
Leverage & solvency
Liabilities / assets97.9%
Debt / equity0.00x
Current ratio2.33x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $154.90M | $144.28M |
| Cost of revenue | $41.35M | $38.65M |
| Gross profit | $113.56M | $105.64M |
| R&D expense | $12.43M | $16.68M |
| SG&A expense | $54.60M | $53.40M |
| Operating income | -$2.54M | -$11.53M |
| Interest expense | $9.61M | $6.03M |
| Income tax | $0 | $0 |
| Net income | -$20.20M | -$13.58M |
| EBITDA | -$224,000 | -$9.04M |
| EPS (basic) | -0.12 | -0.09 |
| EPS (diluted) | -0.12 | -0.09 |
| Weighted avg. shares (diluted) | 166.71M | 152.45M |
| Balance sheet | ||
| Cash & equivalents | $28.65M | $25.80M |
| Short-term investments | $17.98M | $33.48M |
| Receivables | $89.59M | $78.88M |
| Inventory | $92.75M | $53.16M |
| Current assets | $238.07M | $209.01M |
| PP&E, net | $12.40M | $14.86M |
| Total assets | $255.88M | $233.15M |
| Current liabilities | $96.10M | $91.46M |
| Total liabilities | $241.54M | $266.80M |
| Shareholders' equity | $14.33M | -$33.65M |
| Shares outstanding | 188.31M | 152.13M |
| Cash flow statement | ||
| Operating cash flow | -$27.59M | -$22.53M |
| Capital expenditure | $317,000 | $1.71M |
| Free cash flow | -$27.91M | -$24.23M |
| Investing cash flow | $16.01M | $18.71M |
| Financing cash flow | $14.43M | $940,000 |
| Depreciation & amortization | $2.31M | $2.49M |
| Stock-based compensation | $10.34M | $12.96M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.